Refine by MP, party, committee, province, or result type.
Health committee Yes, regarding that last point, I would add only that this is good not only for devices and medication but for vaccine development. We've seen that during the pandemic. We're really dependent on the proper evaluation of vaccines by Health Canada. We need to move in a very efficie
March 21st, 2023Committee meeting
Dr. Alain Lamarre
Health committee Definitely. People working on fighting infectious diseases all agree that we need the highest immunization rates possible. Unfortunately, there are no vaccines that combat all infectious agents. So there are still many more vaccines to be developed. I mentioned the respiratory
March 21st, 2023Committee meeting
Dr. Alain Lamarre
Health committee I would have said the same thing. I would add that, unfortunately, the big pharmaceutical companies have little incentive to develop new antibiotics. It is a very complex and very competitive market. So we have to rely on the research done by universities which, however, depend
March 21st, 2023Committee meeting
Dr. Alain Lamarre
Health committee It's probably even worse than the budget allocated to fundamental research in the G7. Yes, we are second-last in that aspect, and it's probably not better than 20th position in the world for children's research. I think there's a lot of ground to be covered.
March 21st, 2023Committee meeting
Dr. Alain Lamarre
Health committee I wouldn't guess any number, but as other witnesses have said, it's a minority, for sure. There's a lack of funding, in general, but it's probably even more pronounced for children's research. That goes from fundamental research all the way to clinical trials, which are also diff
March 21st, 2023Committee meeting
Dr. Alain Lamarre
Health committee Thank you for your question. It is right on the mark. There is in fact a chronic problem with investment in research in Canada, for the past 20 years or so, I would say, and research budgets have stagnated while costs have risen, meaning that we ultimately have less money to con
March 21st, 2023Committee meeting
Dr. Alain Lamarre
Health committee Thank you, Mr. Chair. I wish to thank the committee for inviting me to this meeting. I am a research professor at the Centre Armand-Frappier Santé Biotechnolgie of the INRS, or National Institute of Scientific Research, Laval. I also hold the Jeanne and J.‑Louis Lévesque chair i
March 21st, 2023Committee meeting
Dr. Alain Lamarre
Industry committee I think, in fact, that what's needed is to create structures, along the lines of what the National Research Council of Canada has done, that are at the junction of university research and the pharmaceutical industry. That would make them independent of the ups and downs of the ma
April 8th, 2022Committee meeting
Dr. Alain Lamarre
Industry committee As I mentioned earlier, I am worried about that. The success rate in CIHR competitions, for example, is declining. It's below 20% in each competition, meaning that excellent research proposals are not being funded. Furthermore, even when a project is funded, 26% to 27% of the res
April 8th, 2022Committee meeting
Dr. Alain Lamarre
Industry committee Thank you.
April 8th, 2022Committee meeting
Dr. Alain Lamarre
Industry committee As I said in my presentation, there were major investments, and some of my colleagues here before the committee spoke about their results. There were the projects I mentioned and several others in development. There was recently an announcement about a new cell and gene therapy m
April 8th, 2022Committee meeting
Dr. Alain Lamarre
Industry committee I do in fact believe that the WHO's position is defensible. Would the WHO be willing to change its rules? Perhaps not, but it's not too late to act, knowing that other investors, or even the federal government, could take over the cigarette manufacturer's stake. I don't believe
April 8th, 2022Committee meeting
Dr. Alain Lamarre
Industry committee I think we'll have to go back to the early days of the company. In passing, I'm not involved in any way with this company. I have no shares in the company and no particular axe to grind about what it does. Based on what I know, in the early start‑up phases of any project, you te
April 8th, 2022Committee meeting
Dr. Alain Lamarre
Industry committee It came as a surprise to me, as it did for many others. My understanding of the situation is that neither the efficacy nor the safety of the Medicago vaccine were at issue. It was rather the company's links to a tobacco manufacturer. The WHO position was known, and is defensible
April 8th, 2022Committee meeting
Dr. Alain Lamarre
Industry committee Thank you, Mr. Chair. First of all, I would like to thank the committee for inviting me to take part in this meeting. The topic you are discussing is essential to ensuring our national security, responding to the COVID‑19 pandemic and, above all, preparing to cope with future pa
April 8th, 2022Committee meeting
Dr. Alain Lamarre